Skip Navigation

Receive this page by email each issue: [Sign up for eTOCs]

Contents: Volume 3, Number 9, November 1992   [Index by Author] 
Other Issues: Previous Next  

Down Articles
Down News
Down Editorials
Down Special articles
Down Review
Down Commentaries
Down Book reviews
Down Original articles
Down Short reports
Down Letters


[Search ALL Issues]

Front Matter (PDF) | Back Matter (PDF)

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.

Articles Back

In this issue
Ann Oncol 1992 3: 667. [PDF] [Request Permissions]  

News Back

Steven Dickman
Researchers home in on the elusive stem cell
Ann Oncol 1992 3: 668-669. [PDF] [Request Permissions]  

Economy measures at IARC, but further danger looms
Ann Oncol 1992 3: 670. [PDF] [Request Permissions]  

First designer drugs in oncology
Ann Oncol 1992 3: 670-671. [PDF] [Request Permissions]  

Thatcher to propagate smoking?
Ann Oncol 1992 3: 671-672. [PDF] [Request Permissions]  

The BMJ got it wrong
Ann Oncol 1992 3: 672. [PDF] [Request Permissions]  

AIDS conference in Amsterdam: Prevalence of social problems and a possible third virus
Ann Oncol 1992 3: 672. [PDF] [Request Permissions]  

Awards, Appointments
Ann Oncol 1992 3: 672-673. [PDF] [Request Permissions]  

Perhaps not everyone knows that...
Ann Oncol 1992 3: 673-674. [PDF] [Request Permissions]  

Editorials Back

James O. Armitage
Editorial: ‘Staging’ systems for aggressive non-Hodgkin's lymphoma
Ann Oncol 1992 3: 675-676. [PDF] [Request Permissions]  

Richard J. Gralla
Editorial: Serotonin antagonist antiemetics: Progress and concerns
Ann Oncol 1992 3: 677-678. [PDF] [Request Permissions]  

T. Cerny and A. Küpfer
Editorial: The enigma of ifosfamide encephalopathy
Ann Oncol 1992 3: 679-681. [PDF] [Request Permissions]  

Special articles Back

R. D. Gelber, A. S. Coates, and A. Goldhirsch
Meta-analysis: The fashion of summing-up evidence: Part II: Interpretations and uses
Ann Oncol 1992 3: 683-691. [Abstract] [PDF] [Request Permissions]  

Review Back

J. K. Cowell
Tumour suppressor genes
Ann Oncol 1992 3: 693-698. [Abstract] [PDF] [Request Permissions]  

Commentaries Back

P. Workman
Commentary: Emerging from a crisis in anticancer drug discovery? Screening versus design: Confessions of an optimistic fence-sitter
Ann Oncol 1992 3: 699-705. [PDF] [Request Permissions]  

B. W. Fox
Commentary: Current results with rhizoxin: The evaluation of a clinical and a basic scientist
Ann Oncol 1992 3: 707-708. [PDF] [Request Permissions]  

S. B. Kaye
Commentary: Current results with rhizoxin: The evaluation of a clinical and a basic scientist
Ann Oncol 1992 3: 708-709. [PDF] [Request Permissions]  

Book reviews Back

F. R. Balkwill
Book review
Ann Oncol 1992 3: 709. [PDF] [Request Permissions]  

F. Cavalli
Book review
Ann Oncol 1992 3: 717. [PDF] [Request Permissions]  

Cristiana Sessa
Book review
Ann Oncol 1992 3: 732. [PDF] [Request Permissions]  

Marco Gasparini
Book review
Ann Oncol 1992 3: 745. [PDF] [Request Permissions]  

Cora N. Sternberg
Book review
Ann Oncol 1992 3: 764. [PDF] [Request Permissions]  

Original articles Back

J. Rodriguez, F. Cabanillas, P. McLaughlin, F. Swan, M. Rodriguez, F. Hagemeister, and J. Romaguera
Original article: A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the ‘tumor score’
Ann Oncol 1992 3: 711-717. [Abstract] [PDF] [Request Permissions]  

A. S. Coates, A. Childs, K. Cox, C. Forsyth, D. F. Joshua, E. McNeil, and J. J. Grygiel
Original article: Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron
Ann Oncol 1992 3: 719-722. [Abstract] [PDF] [Request Permissions]  

C. Manegold, H. Bischoff, J. R. Fischer, S. Löchner, M. Peukert, A. Schmähl, and P. Drings
Original article: Oral ifosfamide-mesna: A clinical investigation in advanced non-small-cell lung cancer
Ann Oncol 1992 3: 723-726. [Abstract] [PDF] [Request Permissions]  

E. F. Vokes, A. P. Lyss, J. E. Herndon, II, B. Cooper, M. C. Perry, V. Vinciguerra, K. Mason-Coughlin, and M. R. Green
Original article: Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: A randomized phase II study of the cancer and leukemia group B
Ann Oncol 1992 3: 727-732. [Abstract] [PDF] [Request Permissions]  

V. Spataro, K. Price, A. Goldhirsch, F. Cavalli, E. Simoncini, M. Castiglione, C.-M. Rudenstam, J. Collins, J. Lindtner, and R. D. Gelber
Original article: Sequential estrogen receptor determinations from primary breast cancer and at relapse: Prognostic and therapeutic relevance
Ann Oncol 1992 3: 733-740. [Abstract] [PDF] [Request Permissions]  

C. N. Sternberg, M. G. Arena, V. Pansadoro, F. Calabresi, I. D'Agnano, P. De Carli, M. Zeuli, A. Cancrini, F. Rosenkaimer, and G. Zupi
Original article: Recombinant tumor necrosis factor for superficial bladder tumors
Ann Oncol 1992 3: 741-745. [Abstract] [PDF] [Request Permissions]  

S. J. Horning, P. T. Ang, R. T. Hoppe, and S. A. Rosenberg
Original article: The Stanford experience with combined procarbazine, Alkeran and vinblastine (PAVe) and radiotherapy for locally extensive and advanced stage Hodgkin's disease
Ann Oncol 1992 3: 747-754. [Abstract] [PDF] [Request Permissions]  

H.R. Hendriks, J. Plowman, D. P. Berger, K. D. Paull, H. H. Fiebig, Ø. Fodstad, H. C. Dreef-van der Meulen, R. E. C. Henrar, H. M. Pinedo, and G. Schwartsman
Original article: Preclinical antitumour activity and animal toxicology studies of rhizoxin, a novel tubulin-interacting agent
Ann Oncol 1992 3: 755-763. [Abstract] [PDF] [Request Permissions]  

Short reports Back

A. M. Testi, M. L. Moleti, F. Gionna, A. R. Iori, G. Meloni, R. Miniero, M. Pigna, S. Amadori, and F. Mandelli
Short report: Treatment of primary refractory or relapsed acute lymphoblastic leukemia (ALL) in children
Ann Oncol 1992 3: 765-767. [Abstract] [PDF] [Request Permissions]  

G. Falkson, R. S. Gelman, J. Glick, C. I. Falkson, and J. Harris
Short report: Metastatic breast cancer: Higher versus low dose maintenance treatment when only a partial response or a no change status is obtained following doxorubicin induction treatment: An Eastern Cooperative Oncology Group Study
Ann Oncol 1992 3: 768-770. [PDF] [Request Permissions]  

Letters Back

E. Aitini, E. Pasquini, G. Cavazzini, P. P. Fattori, and F. Smerieri
Local treatment of malignant pleural mesothelioma with intracavitary cytosine-arabinoside and cisplatin
Ann Oncol 1992 3: 771-772. [PDF] [Request Permissions]  

C. Bokemeyer, M. Freund, H.-J. Schmoll, H. Rieder, and C. Fonatsch
Secondary lymphoblastic leukemia following treatment of a malignant germ cell tumour
Ann Oncol 1992 3: 772. [PDF] [Request Permissions]  

W. M. Castle, K. Cunningham, and B. B. Kanarek
Controversy on ondansetron: Ondansetron is not associated with vascular adverse events, thrombocytopenia or renal failure
Ann Oncol 1992 3: 773-774. [PDF] [Request Permissions]  

A. S. Coates, A. Childs, K. Cox, C. Forsyth, D. E. Joshua, E. McNeil, and J. Grygiel
The above letter was referred to the authors, who respond as follows:
Ann Oncol 1992 3: 774. [PDF] [Request Permissions]  

S. Aamdal
Can ondansetron hydrochloride (Zofran®) enhance the nephrotoxic potential of other drugs?
Ann Oncol 1992 3: 774. [PDF] [Request Permissions]  

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.